AbbVie stock trades within 7-day range with buyers dominating overbought market

Traders Union
All News
Financial News
AbbVie slips 0.46% this week

Highlights

AbbVie maintains a strong medium- and long-term bullish technical structure, currently trading above all major moving averages.
Momentum indicators are mixed, with MACD and Awesome Oscillator supporting upside but Stochastic RSI and Bull/Bear suggest overbought and consolidation.
Expected trading range is $214.50 to $242.30 for the coming week, with a sideways bias and breakout levels clearly defined.

Drug trial success and deals drive bullish sentiment over the week

AbbVie announced positive topline results from a Phase 1 clinical trial of its investigational obesity drug, ABBV-295, showing significant, dose-dependent weight loss in adults with overweight or obesity and a favorable safety profile. The company also reported encouraging Phase 3 results for risankizumab in Crohn’s disease, supporting further label expansion efforts. In addition, AbbVie signed a license agreement with Gubra A/S to continue development of ABBV-295.

Mixed momentum signals as weekly action consolidates amid overbought technicals

On the weekly (W1) timeframe, AbbVie is firmly positioned above all major moving averages, reinforcing the prevailing bullish structure. The MA-20 at $225.76 provides the nearest key support, while the MA-50 and MA-200 at $209.99 and $174.20 offer deeper support zones. Weekly volatility stands at 6.15%. Momentum signals are mixed: the MACD is on Strong Buy, the ADX is Neutral, RSI is in buying territory but the Stochastic RSI shows mid-level selling pressure, and Bull/Bear Power indicates an overbought market with buyer dominance. The Awesome Oscillator also confirms overall buying pressure. The stock's movement this week reflects consolidation following a steady decline from the recent weekly high.

Sideways bias expected as volatility and divergent signals shape next week

For the next 5 to 7 trading days, AbbVie is expected to consolidate within the $214.50 to $242.30 range, in line with current volatility and technical levels. Given mixed momentum signals, there is an approximately equal probability of further upside or downside. A bullish breakout above $242.30 may push prices to new highs, while a break below $214.50 could lead to deeper declines. Baseline scenario favors sideways movement within the current corridor.

Anton Kharitonov, Traders Union expert, notes that AbbVie held above major moving averages this week, but its slight decline and mixed momentum create caution. Technically, the bullish medium- and long-term structure remains intact, with the MA-20 at $225.76 acting as the nearest support. However, signals like an overbought Bull/Bear Power and selling pressure on the Stochastic RSI limit near-term optimism. Positive news from clinical trials and collaboration agreements support fundamental sentiment, yet weekly price action suggests consolidation rather than renewed upside. Kharitonov sees roughly equal probabilities for a break above $242.30 or below $214.50 in the coming days, but prefers a defensive, wait-and-see stance. "Until we see a clear breakout from the current range, I remain cautious and will not chase any upside moves."

Last time, analysts noted that AbbVie Inc. was maintaining a bullish structure across short-, medium-, and long-term trends, with its price above key moving averages and supported by positive signals from drug pipeline developments, despite heightened volatility and insider selling. Near-term technicals indicate overbought conditions and weak trend momentum, with key support around $220 and resistance at $234, suggesting a probable range-bound consolidation with an upside bias unless a break below support triggers further declines.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.